Sector News

GlobeImmune axes ‘majority’ of staffers in wake of trial failure

June 10, 2015
Life sciences
Two weeks after GlobeImmune conceded that its Gilead-partnered hepatitis B vaccine had flunked out of a key Phase II study, the Louisville, CO-based biotech said it laid off “the majority” of its staff.
 
“Following our recent data announcement in our hepatitis B program, this workforce reduction is a necessary action to conserve working capital and provide maximum flexibility in determining the future direction of GlobeImmune,” said GlobeImmune CEO Timothy Rodell in a statement.
 
Recruiting 178 patients with chronic hep B, GlobeImmune tested GS-4774 in combination with standard oral antivirals, finding that the vaccine charted no improvement in hep B surface antigen levels, a key measure of viral activity, compared to the older drugs alone. At 24 weeks, even the highest doses of GS-4774 failed to meet the study’s primary endpoint, GlobeImmune said, though the vaccine did chart a positive–but not statistically significant–effect after 48 weeks.
 
Pointing to three patients who got the highest dose and posted notable surface antigen reductions, GlobeImmune said at the time that it believed the trial “suggests initial biologic activity” for GS-4774. The vaccine was also safe and well tolerated in the study, the company said.
 
Investors were less optimistic, sending the company’s shares into a meltdown that wiped out half of its market cap.
 
By John Carroll
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach